Joanna E Zawacka-Pankau

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5944081/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Role of p53 Family in Cancer. Cancers, 2022, 14, 823.	3.7	17
2	Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule. Frontiers in Molecular Biosciences, 2022, 9, .	3.5	3
3	The Therapeutic Potential of the Restoration of the p53 Protein Family Members in the EGFR-Mutated Lung Cancer. International Journal of Molecular Sciences, 2022, 23, 7213.	4.1	4
4	The Changes in the p53 Protein across the Animal Kingdom Point to Its Involvement in Longevity. International Journal of Molecular Sciences, 2021, 22, 8512.	4.1	9
5	The Undervalued Avenue to Reinstate Tumor Suppressor Functionality of the p53 Protein Family for Improved Cancer Therapy-Drug Repurposing. Cancers, 2020, 12, 2717.	3.7	8
6	The p53/MDM2/MDMX-targeted therapies—a clinical synopsis. Cell Death and Disease, 2020, 11, 237.	6.3	45
7	Protoporphyrin IX is a dual inhibitor of p53/MDM2 and p53/MDM4 interactions and induces apoptosis in B-cell chronic lymphocytic leukemia cells. Cell Death Discovery, 2019, 5, 77.	4.7	24
8	Activation of TAp73 and inhibition of TrxR by Verteporfin for improved cancer therapy in <i>TP53</i> mutant pancreatic tumors. Future Science OA, 2019, 5, FSO366.	1.9	16
9	APR-246 reactivates mutant p53 by targeting cysteines 124 and 277. Cell Death and Disease, 2018, 9, 439.	6.3	182
10	Reactivation of TAp73 tumor suppressor by protoporphyrin IX, a metabolite of aminolevulinic acid, induces apoptosis in TP53-deficient cancer cells. Cell Division, 2018, 13, 10.	2.4	15
11	Mutant p53 talks to proteasomes—is there a feedback loop between Nrf2 and mutant p53?. Translational Cancer Research, 2016, 5, 733-737.	1.0	0
12	The use of ion mobility mass spectrometry to probe modulation of the structure of p53 and of MDM2 by small molecule inhibitors. Frontiers in Molecular Biosciences, 2015, 2, 39.	3.5	30
13	Pharmacological reactivation of p53 as a strategy to treat cancer. Journal of Internal Medicine, 2015, 277, 248-259.	6.0	71
14	p53 family members – important messengers in cell death signaling in photodynamic therapy of cancer?. Photochemical and Photobiological Sciences, 2015, 14, 1390-1396.	2.9	26
15	JNK–NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress. Cell Death and Disease, 2014, 5, e1484-e1484.	6.3	33
16	ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis. Cell Death and Differentiation, 2014, 21, 612-623.	11.2	193
17	Plumbagin Induces Apoptosis in Her2-Overexpressing Breast Cancer Cells through the Mitochondrial-Mediated Pathway. Journal of Natural Products, 2012, 75, 747-751.	3.0	51
18	Induction of Apoptosis in HL-60 Cells through the ROS-Mediated Mitochondrial Pathway by Ramentaceone from <i>Drosera aliciae</i> . Journal of Natural Products, 2012, 75, 9-14.	3.0	56

JOANNA E ZAWACKA-PANKAU

#	Article	IF	CITATIONS
19	Targeting of p53 and its homolog p73 by protoporphyrin IX. FEBS Letters, 2011, 585, 255-260.	2.8	19
20	Inhibition of Glycolytic Enzymes Mediated by Pharmacologically Activated p53. Journal of Biological Chemistry, 2011, 286, 41600-41615.	3.4	101
21	Evaluation of the Role of the Pharmacological Inhibition of <i>Staphylococcus aureus</i> Multidrug Resistance Pumps and the Variable Levels of the Uptake of the Sensitizer in the Strainâ€Dependent Response of <i>Staphylococcus aureus</i> to PPArg ₂ â€Based Photodynamic Inactivation. Photochemistry and Photobiology. 2010. 86. 1118-1126.	2.5	26
22	p73 tumor suppressor protein: A close relative of p53 not only in structure but also in anti-cancer approach?. Cell Cycle, 2010, 9, 720-728.	2.6	60
23	p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA. Cell Cycle, 2009, 8, 3584-3591.	2.6	81
24	Enlightened protein: Fhit tumor suppressor protein structure and function and its role in the toxicity of protoporphyrin IX-mediated photodynamic reaction. Toxicology and Applied Pharmacology, 2009, 241, 246-252.	2.8	3
25	Aberration of the enzymatic activity of Fhit tumor suppressor protein enhances cancer cell death upon photodynamic therapy similarly to that driven by wild-type Fhit. Cancer Letters, 2009, 280, 101-109.	7.2	4
26	The p53-mediated cytotoxicity of photodynamic therapy of cancer: Recent advances. Toxicology and Applied Pharmacology, 2008, 232, 487-497.	2.8	57
27	Protoporphyrin IX Interacts with Wild-type p53 Protein in Vitro and Induces Cell Death of Human Colon Cancer Cells in a p53-dependent and -independent Manner. Journal of Biological Chemistry, 2007, 282, 2466-2472.	3.4	51
28	Tumor suppressor Fhit protein interacts with protoporphyrin IX in vitro and enhances the response of HeLa cells to photodynamic therapy. Journal of Photochemistry and Photobiology B: Biology, 2007, 86, 35-42.	3.8	14
29	Expression and simple, one-step purification of fragile histidine triad (Fhit) tumor suppressor mutant forms in Escherichia coli and their interaction with protoporphyrin IX. Biotechnology Letters, 2007, 29, 877-883.	2.2	4
30	Protoporphyrin IX induces apoptosis in HeLa cells prior to photodynamic treatment. Pharmacological Reports, 2007, 59, 474-9.	3.3	27